Workera finds pharma staff score lower on responsible AI skills

Workera says its assessment of nearly 9,400 employees across pharmaceutical companies found a 14-point gap between foundational generative AI skills and responsible AI use. In a sector where AI decisions can touch clinical trials and patient care, that is a gap worth measuring, not merely hoping away.

Workera Watch analysis

What happened

Workera’s article says employees reached 82% readiness in foundational generative AI skills, compared with 68% in responsible AI. The assessment covered 105 capabilities across nearly 90 programmes, with participation from departments ranging from commercial teams to research and development.

The company also says employees who took a follow-up assessment improved their scores by a median of 42%, with reassessment happening an average of 14 days later. These are Workera’s figures from its own programmes, not an independent sector-wide study.

Why it matters

The difference between knowing how to use an AI tool and knowing when its use is inappropriate matters especially in pharmaceuticals. Workera points to trial protocols, safety-signal reviews and regulatory submissions as places where poor judgement could carry consequences beyond a disappointing quarterly report.

The numbers suggest that measuring responsible use separately from basic AI familiarity can reveal a capability gap that broad training-completion figures might miss. They do not show that every pharma workforce has the same gap, or that a short-term score rise translates into safer decisions on the job.

Our read

The useful takeaway is not that pharma workers are failing an AI test. It is that “AI-ready” can conceal two very different things: operating a tool and judging its limits. Workera’s results make a case for assessing both, while its commercial interest is a good reason to treat the figures as a signal rather than a sector verdict.

What to watch

• Whether Workera publishes details on how readiness was assessed and how participating programmes were selected.
• Whether follow-up gains persist beyond the first reassessment.
• Whether pharmaceutical companies report comparable results from their own assessments.

Discussion spark: Should pharmaceutical companies have to demonstrate staff competence in responsible AI use before deploying AI in patient-affecting work, or is that too blunt a test?

not affiliated with or endorsed by Workera